5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Average Time Under pCPA Consideration Below 30 Days for the 3rd Consecutive Month

October 16, 2019
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights

 

The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations.  Highlights since the last update include:

  • 4 products completed CADTH review, for a total of 6 files under consideration;
  • 8 products initiated pCPA negotiations, for a total of 48 active negotiations;
  • 6 negotiations completed for a total of 276 completed negotiations;
  • 1 negotiation closed, for a total of 45 closed negotiations; and
  • 1 file closed without negotiations, for a total of 69 declined negotiations.

 

Files Under pCPA Consideration

4 new drug products received a CDEC recommendation or pERC notification to implement in September 2019, for a total of approximately 6 products under pCPA Consideration.

 

Brand Name Generic Name Manufacturer Indication Recommendation
Darzalex Daratumumab Janssen Multiple Myeloma (newly diagnosed) Conditional
Lonsurf Trifluridine and Tipiracil Taiho Pharma Metastatic Colorectal Cancer
Do Not Reimburse
Iluvien fluocinolone acetonide intravitreal implant Knight Therapeutics Diabetic Macular Edema
Do Not Reimburse
Dovato dolutegravir/lamivudine ViiV Healthcare HIV-1 Infection Conditional

 

Negotiation Initiation

The pCPA initiated 8 new negotiations since the last update, for a total of 48 active negotiations.

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Initiate
Keytruda Pembrolizumab Merck Melanoma adjuvant therapy 19 Aug 19 27 days
Lutathera Lutetium Lu-177 Advanced Accelerator Applications Midgut neuroendocrine tumours 19 Aug 19 27 days
Lenvima Lenvatinib Eisai Unresectable hepatocellular carcinoma, first line 9 Aug 19 37 days
Olumiant Baricitinib Eli Lilly Rheumatoid Arthritis 2 Aug 19 44 days
Verzenio Abemaciclib Eli Lilly Advanced or metastatic breast cancer 22 Jul 19 55 days
Revlimid Lenalidomide Celgene Multiple myeloma 5 Jul 19 72 days
Radicava Edaravone Mitsubishi Tanabe Amyotrophic lateral sclerosis 27 Mar 19 172 days
Truxima Rituximab Teva Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma N/A N/A

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

 

Signals Decoded:

The number of files Under pCPA Consideration has been adjusted to remove (as of July 2019) Cinqair, Fasenra and Nucala. All 3 had received CADTH recommendations on March 27, 2019 based on a Request for Advice. Given recent updates to the ODB formulary, it appears that no new negotiations will be initiated for these products at this time, and that any administrative/criteria changes stemming from the Request for Advice, will be implemented at the jurisdictional level.

 

 

Completed

 

Brand Name Generic Name Manufacturer Indication Initiated Duration*
Blincyto Blinatumomab Amgen Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia Jul 2019 62 days
Opdivo Nivolumab BMS Adjuvant treatment of melanoma Jun 2019 92 days
Velphoro Sucroferric oxyhydroxide Vifor Hyperphosphatemia in end stage renal disease Apr 2019 153 days
Fulphila Pegfilgrastim BGP Pharma Febrile neutropenia in non-myeloid malignancies Feb 2019 212 days
Dupixent Dupilumab Sanofi Genzyme Atopic Dermatitis Nov 2018 304 days
Trelegy Ellipta Fluticasone furoate + umecilidinium/vilanterol GlaxoSmithKline Chronic obstructive pulmonary disease Nov 2018 304 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

Closed

 

Brand Name Generic Name Manufacturer Indication Initiation Duration*
Trulicity Dulaglutide Eli Lilly Type 2 Diabetes Mellitus Jul 2017 792 days

 

 

Signals Decoded:

September saw the completion of negotiations for new indications for Blincyto (4th) and Opdivo (5th). September also saw the closure of Trulicity – one of the two negotiations (other is Kuvan) that have been active for more than 2 years..

 

Not Negotiated

 

Brand Name Generic Name Manufacturer Indication CADTH Date Time to Decision*
Alunbrig Brigatinib Takeda ALK positive locally advanced or metastatic non-small cell lung cancer 19 Aug 19 27 days

*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
Update on the CanREValue Collaboration
NEXT POST →
NEW Canadian Reimbursement Trends and Timelines Report – now available!

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Average Time Under pCPA Consideration Below 30 Days for the 3rd Consecutive Month